{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Faye M"],"funding":["GlaxoSmithKline","Agence Nationale de la Recherche","Recherche Clinique","MSD France","Fresenius Medical Care","The Inserm","Merck Sharp &amp; Dohme","Programme hospitalier de recherche clinique","Sanofi"],"pagination":["1588-1597"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9718050"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(11)"],"pubmed_abstract":["<h4>Background and objectives</h4>Late stages of CKD are characterized by significant symptom burden. This study aimed to identify subgroups within the 5-year trajectories of symptom evolution in patients with CKD and to describe associated patient characteristics and outcomes.<h4>Design, setting, participants, & measurements</h4>Among 2787 participants (66% men) with eGFR <60 ml/min per 1.73 m<sup>2</sup> enrolled in the CKD-Renal Epidemiology and Information Network (CKD-REIN) cohort study from July 2013 to May 2016, we assessed symptoms annually using the Kidney Disease Quality of Life-36 (KDQOL-36) questionnaire until December 2020. A total of 9121 measures were reported over follow-up; all participants had symptoms scored for at least one time point. We used a joint latent class-mixed model to distinguish profiles of symptom trajectories.<h4>Results</h4>Patient mean age (±SD) at baseline was 67±13 years, and mean eGFR was 33±13 ml/min per 1.73 m<sup>2</sup>. The prevalence of each symptom ranged from 24% (chest pain) to 83% (fatigue), and 98% of participants reported at least one symptom. After a median (interquartile range) follow-up of 5.3 (3.4-6.0) years, 690 participants initiated KRT, and 490 died before KRT. We identified two profiles of symptom trajectories: a \"worse symptom score and worsening trajectory\" in 31% of participants, characterized by a low initial symptom score that worsened more than ten points over time, and a \"better symptom score and stable trajectory\" in 69% of participants, characterized by a high initial score that remained stable. Participants in the worse symptom score and worsening trajectory group had more risk factors for CKD progression at baseline, worse quality of life, and a higher risk of KRT and death before KRT than other participants.<h4>Conclusions</h4>This study highlights a significant worsening of symptoms in about one third of the participants, whereas the majority reported low symptom severity throughout the study."],"journal":["Clinical journal of the American Society of Nephrology : CJASN"],"pubmed_title":["Five-Year Symptom Trajectories in Nondialysis-Dependent CKD Patients."],"pmcid":["PMC9718050"],"funding_grant_id":["ANR-IA-COH-2012/3731"],"pubmed_authors":["Legrand K","Liabeuf S","Massy ZA","CKD-REIN Study Group","Fouque D","Le Gall L","Speyer E","Leffondre K","Ayav C","Alencar de Pinho N","Faye M","Pecoits Filho R","Laville M","Jacquelinet C","Stengel B","Frimat L","Omorou AY","Combe C"],"additional_accession":[]},"is_claimable":false,"name":"Five-Year Symptom Trajectories in Nondialysis-Dependent CKD Patients.","description":"<h4>Background and objectives</h4>Late stages of CKD are characterized by significant symptom burden. This study aimed to identify subgroups within the 5-year trajectories of symptom evolution in patients with CKD and to describe associated patient characteristics and outcomes.<h4>Design, setting, participants, & measurements</h4>Among 2787 participants (66% men) with eGFR <60 ml/min per 1.73 m<sup>2</sup> enrolled in the CKD-Renal Epidemiology and Information Network (CKD-REIN) cohort study from July 2013 to May 2016, we assessed symptoms annually using the Kidney Disease Quality of Life-36 (KDQOL-36) questionnaire until December 2020. A total of 9121 measures were reported over follow-up; all participants had symptoms scored for at least one time point. We used a joint latent class-mixed model to distinguish profiles of symptom trajectories.<h4>Results</h4>Patient mean age (±SD) at baseline was 67±13 years, and mean eGFR was 33±13 ml/min per 1.73 m<sup>2</sup>. The prevalence of each symptom ranged from 24% (chest pain) to 83% (fatigue), and 98% of participants reported at least one symptom. After a median (interquartile range) follow-up of 5.3 (3.4-6.0) years, 690 participants initiated KRT, and 490 died before KRT. We identified two profiles of symptom trajectories: a \"worse symptom score and worsening trajectory\" in 31% of participants, characterized by a low initial symptom score that worsened more than ten points over time, and a \"better symptom score and stable trajectory\" in 69% of participants, characterized by a high initial score that remained stable. Participants in the worse symptom score and worsening trajectory group had more risk factors for CKD progression at baseline, worse quality of life, and a higher risk of KRT and death before KRT than other participants.<h4>Conclusions</h4>This study highlights a significant worsening of symptoms in about one third of the participants, whereas the majority reported low symptom severity throughout the study.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2026-05-28T22:36:21.191Z","creation":"2026-04-08T03:23:59.71Z"},"accession":"S-EPMC9718050","cross_references":{"pubmed":["36307136"],"doi":["10.2215/CJN.06140522","10.2215/cjn.06140522"]}}